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SUMMARY 
 
Background 
The Finnish Invasive Pneumococcal disease (FinIP) vaccine trial was designed to demonstrate the 
vaccine effectiveness (VE) of 10-valent PHiD-CV (GlaxoSmithKline) against invasive pneumococcal 
disease (IPD).  
 
Methods 
In this cluster-randomised, double-blind trial, children aged <19 months received PHiD-CV10 in two 
thirds of clusters (N=52) or hepatitis vaccines as control in 26 clusters. Infants aged <7 months at the 
first vaccination received either a 3+1 or a 2+1 vaccination schedule, children aged 7-11 months 
received a 2+1 schedule and children 12-18 months a two-dose schedule. The primary and secondary 
objectives were to demonstrate VE against culture-confirmed IPD due to any of the 10 vaccine 
serotypes for the 3+1 and 2+1 schedules, respectively, in children who received at least one PHiD-
CV10 dose <7 months of age. Blinded IPD follow-up lasted from the first vaccination (from February 
2009 through October 2010) to January 31, 2012. IPD data were retrieved from data accumulated in 
the National Infectious Diseases Register. This trial and nested AOM trial are registered at 
ClinicalTrials.gov, NCT00861380/NCT00839254. 
 
Findings 
Altogether, 47 366 children were enrolled. In 30 527 subjects evaluated for the primary objective, 13 
culture-confirmed vaccine-type IPD cases were detected: 0 in the PHiD-CV10 3+1, 1 in PHiD-CV10 
2+1, and 12 in control groups. The VE estimates were 100% (95%CI 83-100) for PHiD-CV10 3+1, 
and 92% (58-100) for PHiD-CV10 2+1 groups. Two cases of any culture-confirmed IPD irrespective 
of serotype were detected in combined PHiD-CV10 infant cohorts compared to 14 in the 
corresponding control cohorts (VE 93%, 75-99). In catch-up cohorts, seven IPD cases were reported; 
all in the control group; 2 in the children enrolled 7-11 months and 5 in children enrolled 12-18 
months of age (VE 100%, 79-100). 
 
Interpretation 
This nationwide trial demonstrated high PHiD-CV10 effectiveness against IPD when given in 
different schedules. For the first time, effectiveness of a 2+1 schedule in infants was confirmed in a 
clinical trial.  
 
Funding 
GlaxoSmithKline Biologicals SA and National Institute for Health and Welfare (THL), Finland 
 
Registration: ClinicalTrials.gov, NCT00861380 and NCT00839254. 
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Panel: Research in context 
 
Systematic review 
We searched PubMed and Cochrane Library for reports published in English before September 17, 
2012, with the following search terms in title or abstract text: “efficacy” or “effectiveness” and 
“pneumococcal”, “conjugate vaccine”, “clinical trial”, ”infants”, and “invasive”. In total, 4 clinical 
trials with PCV7 or PCV9 in the USA and Africa were identified. No clinical trial data were 
published with 2+1 infant schedule. Observational effectiveness data for both schedules of PCV7 
(3+1, 2+1), used in national vaccination programmes has accumulated from several countries, but 
only one published report is available for PHiD-CV10. 
 
Interpretation 
The pneumococcal conjugate vaccine PHiD-CV10 given either in 3+1 or 2+1 infant schedule protects 
from invasive pneumococcal disease with high vaccine effectiveness (VE) of 93% (95% confidence 
interval 75 to 99). Catch-up vaccination schedules of children 7-11 and 12-18 months at first dose 
were also shown to be effective against IPD with 100% VE. This is the first European double blind 
randomised controlled trial to document PCV effectiveness against IPD and the first globally 
demonstrating the effectiveness of an infant 2+1 schedule as well as effectiveness of the catch-up 
vaccinations.  
 
Disclosure of results before publication 
The data have been partially presented at the 30th Annual Meeting of the European Society for 
Paediatric Infectious Diseases (ESPID) at Thessaloniki, Greece, May 8-12, 2012. 
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INTRODUCTION 
 
Widespread use of the first 7-valent pneumococcal CRM-conjugate vaccine (PCV7, 
Prevenar/Prevnar™, Pfizer Inc) has resulted in significant reduction of invasive pneumococcal 
disease (IPD) among vaccinated children on several continents.
1–6
 IPD has also decreased among 
unvaccinated populations (herd protection). However, an increase in IPD caused by pneumococcal 
serotypes other than those contained in the vaccine (replacement) has been detected both in 
vaccinated and unvaccinated populations.
4-7
 
 
Another pneumococcal vaccine containing ten serotype-specific polysaccharides conjugated to 
Haemophilus influenzae protein D, tetanus toxoid and diphtheria toxoid as the carrier proteins was 
developed (PHiD-CV10).
8–10
 It was licensed in EU in March 2009 (Synflorix™, GlaxoSmithKline 
Vaccines) based on PHiD-CV10 immunological data according to criteria recommended by WHO
11
 
for licensure for protection against IPD, PHiD-CV10 safety data, and efficacy results of the 11-valent 
precursor formulation against acute otitis media.
12
 
 
The Finnish Invasive Pneumococcal disease (FinIP) vaccine trial was designed to demonstrate the 
clinical vaccine effectiveness (VE) of PHiD-CV10 against IPD. To enable unbiased evaluation of the 
total effectiveness in vaccinated children and subsequently the indirect effectiveness in unvaccinated 
populations we used a cluster randomised clinical field-trial design.  
 
Here, we report the PHiD-CV10 effectiveness against IPD in vaccinated children.  
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METHODS  
 
Trial design 
The FinIP vaccine trial was a controlled, cluster-randomised, double-blind field trial conducted in 
Finnish health care centres (HCC) designed to demonstrate effectiveness of the PHiD-CV10 against 
IPD in infants. A parallel acute otitis media (AOM) trial conducted by the Tampere University 
Vaccine Research Centre (TAUVRC) had the same cluster-randomised design and its subjects were 
also evaluated in this study.
 13
 
 
Participants 
In fall 2008, public municipal HCCs of mainland Finland (212 out of 237) were invited to participate 
excluding Northern Lapland and small HCCs for logistic reasons. Altogether 139 HCCs covering 77% 
(46,000/60,000) of the national birth cohort accepted the invitation. Enrolment and vaccinations were 
performed in local well-baby clinics (WBC, N=651) by the nurses (N>2,200) who are responsible for 
routine health follow-up and immunisations. The WBC visits are scheduled at 
1/2/3/4/5/6/8/10/12/18/24 months of age, including physician’s check-up at 1/4/8/18 months. 
Practically all infants attend WBCs regularly. 
 
The National Institute for Health and Welfare (THL) sent study information letters to Finnish- and 
Swedish-speaking parents/legal guardians of all children born in the study area from December 2007 
through May 2010. WBC nurses (and physicians when needed) gave oral information and obtained 
the written informed consent from the parent/legal guardian. TAUVRC enrolled subjects at 15 
different dedicated study clinics. The child could be enrolled from 6 weeks to 18 months of age 
provided that he/she had not received, and was not anticipated to receive any of the study vaccines, 
nor had any study vaccine-specific or general contraindications to immunisations.  
 
The enrolment ended, as planned, when PCV was introduced in the Finnish National Vaccination 
Programme (NVP) in September 2010 for children born on June 1, 2010 or later.  
 
Study vaccines  
The pneumococcal study vaccine consisted of 1 µg of each capsular polysaccharide (PS) for serotypes 
1, 5, 6B, 7F, 9V, 14 and 23F, and 3 µg for serotype 4 each individually conjugated to protein D of 
nontypeable Haemophilus influenzae, 3 µg of capsular polysaccharide of serotypes 18C and 19F 
conjugated to tetanus and diphtheria toxoids, respectively.  
 
Hepatitis B virus (HBV) vaccine (ENGERIX-B 10 µg/0·5 ml™) was used as a control vaccine for 
children enrolled under 12 months of age and hepatitis A virus (HAV) vaccine (Havrix 720 Junior™) 
for children enrolled at the age of 12 months or older. All study vaccines were manufactured by GSK 
Vaccines. 
 
Vaccinations 
Children enrolled under 7 months of age received 3 (minimum 4-week intervals) or 2 (minimum 8-
week interval) primary vaccinations followed by a booster dose at least 4 months after the last 
primary dose, not earlier than at 11 months of age. Children enrolled between 7 to 11 months of age 
received two doses at least 4 weeks apart and a booster dose at least 4 months after the second 
primary dose. Children enrolled between 12 to 18 months of age received two doses at least 6 months 
apart. The study vaccines were administered concomitantly with the NVP vaccines (Appendix table 1) 
at the scheduled visits. 
 
Cluster randomisation and masking  
The areas of the participating HCCs were divided geographically into 72 clusters taking into account 
administrative structures (WBC/HCC/municipality) and the birth cohort size, which ranged from 322 
to 1127 (mean 636) per cluster. Eleven municipalities covered exclusively by TAUVRC were divided 
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into 6 additional clusters with yearly birth cohorts ranging from 785 to 1472 (total birth cohort 7600). 
The treatments were allocated to the 78 clusters using two infant schedules (3+1/2+1) and a 
randomisation ratio of 2:2:1:1 (PHiD-CV10-3+1:PHiD-CV10-2+1:Control-3+1:Control-2+1, Figure 
1). Treatment allocation was stratified according to the size of the birth cohort (below/above average), 
TAUVRC trial enrolment (50 of 78 clusters), and urbanity (24 urban, 54 rural clusters). Balance was 
also ensured in the six additional TAUVRC clusters and in six clusters in Southwest Finland (Turku 
area) assigned for detailed respiratory infection assessment. Minimisation algorithm
14
 was used to 
obtain a reasonable 2:2:1:1 treatment balance according to the stratification factors. 
 
In each cluster and each WBC, all children received either PHiD-CV or control vaccine as the blinded 
study vaccine. If the child moved from one cluster to another, the original vaccination series was 
continued without unblinding. 
 
Each WBC was provided with two boxes of identical study vaccine vials: one for children enrolled 
before 12 months (PHiD-CV10 or HBV) and another for children enrolled at an older age (PHiD-
CV10 or HAV). Each cluster was assigned a unique randomisation code. TAUVRC trial used a 
different tool for randomisation with individual randomisation codes, which were aligned with the 
randomisation of the main study based on subject's residence. Any medical need for vaccinations 
against pneumococcal disease or hepatitis were handled in a double-blind fashion by allocating the 
hepatitis vaccination to those randomised to the PHiD-CV10 group and vice versa. The number or the 
borders of the clusters were not revealed to participants or WBC nurses and physicians. The clinicians 
diagnosing and treating IPD were not otherwise involved in the trial conduct. The investigators were 
kept blinded to the subject and cluster details of the IPD cases occurring during the study.  
 
Outcomes 
The invasive disease outcome data were collected through the National Infectious Diseases Register 
(NIDR) at THL, which is a laboratory-based surveillance system for collection of cases of diseases 
due to defined pathogens. Reporting of diagnostic findings for blood and/or cerebrospinal fluid 
cultures all around Finland to this register is mandatory for all laboratories and performed 
electronically. It is also obligatory to send the bacterial isolates of defined species to the THL 
laboratory for species verification, archiving and further typing. For S. pneumoniae, serotyping by 
multiplex-PCR supplemented with the Quellung reaction when needed is routinely conducted.
15
 
Culture-confirmed IPD was defined as any disease where S. pneumoniae was isolated from normally 
sterile body fluids by culture. Probable IPD was defined by demonstration of S. pneumoniae based on 
nucleic acid and/or antigen detection tests only, without isolation by culture. 
 
Serious and/or unexpected adverse reactions following immunisation were collected from the national 
vaccine adverse reaction register maintained at THL. WBCs nurses were specifically requested to 
report all deaths, which were also searched from the Population Information System. Results of safety 
follow-up from the TAUVRC trial will be reported separately.  
 
Cohorts and follow-up definitions 
Infant cohorts in the 3+1 and 2+1 clusters comprised of infants who received the first vaccine dose 
before 7 months of age. The two control groups with 3+1 and 2+1 schedules were combined for the 
effectiveness analyses. There were two catch-up cohorts: children receiving the first study vaccination 
at 7-11 months of age and those receiving it at 12-18 months of age. 
 
Intention-to-treat (ITT) follow-up started at the date of the first vaccination. According-to-protocol 
(ATP) follow-up period defined only for infants enrolled before 7 months of age started two weeks 
after the last primary dose. Subjects with protocol violation were eliminated from the ATP follow-up. 
Both blinded follow-up periods for IPD ended on January 31, 2012. 
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Sample size estimation and statistical analysis 
The primary objective was to demonstrate VE against culture-confirmed IPD due to any of the 10 
vaccine serotypes in children who received at least one PHiD-CV10 dose <7 months of age in the 3+1 
schedule. The trial was powered to show a significant difference (alpha=0·05) in vaccine-type IPD 
rate between 3+1 PHiD-CV10 and control arms in the infant cohort. NIDR data from years 2004-
2008, grouped according to age and trial clusters, was used to estimate vaccine-type IPD rates and 
between-cluster variability. Between-cluster coefficient of variation (CV)
16
 was estimated as 0·12 and 
calculations at the end of recruitment with final number of enrolled subjects showed that 12 vaccine-
type IPD cases were expected to occur in the control group by the end of January 2012. The study 
power was estimated through simulation to be 91%, assuming 12 vaccine-type IPD cases to occur in 
the control clusters, VE of 90%, and 0·12 between-cluster CV. CV of 0·12 indicates low or at most 
moderate between-cluster variability.
17
 
Negative binomial model, allowing for possible overdispersion due to cluster design,
16
 was the 
method chosen prior to unblinding for the primary analysis. IPD frequencies were grouped by cluster 
and the cluster-specific person-years were used as weights in the analysis. Factors used for stratified 
randomisation were included in the model as explanatory variables. In case of non-convergence, the 
model without stratification factors was applied and in case of non-convergence of the over-
dispersion parameter (i.e. negligible design effect), Poisson regression was used. Likelihood ratio (LR) 
test
18
 between models with and without the treatment variable was used as the test for significance. In 
order to match with the LR-test and to account for zero cases in the treatment group, profile 
likelihood method
18
 was used to estimate the 95% confidence interval for the treatment parameter. VE 
was calculated as 1 minus rate ratio. 
 
The study protocols were submitted to the relevant ethical review boards and competent authorities 
prior to trial start. The protocol is available at www.finip.fi. This trial and nested AOM trial are 
registered at ClinicalTrials.gov, NCT00861380 and NCT00839254. 
 
Role of the funding source 
GlaxoSmithKline Biologicals SA was the main funding source and National Institute for Health and 
Welfare (THL) co-funded this collaborative study. 
 
Both parties were involved in all stages of the study planning, conduct, data collection, analysis and 
manuscript development. In terms of Good Clinical Practice, GSK had the role of the sponsor and 
THL researchers had the role of the investigator.  
 
All authors had access to all the data in the study and accepted responsibility for its validity. All 
authors agreed on the final decision to submit for publication. 
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RESULTS 
 
Participant flow and baseline data 
From February 18, 2009 through October 5, 2010, a total of 47 366 children were enrolled; 41 188 
children at the well-baby clinics and 6 178 at the TAUVRC clinics. Of the roughly 125 000 children 
invited to participate, 38% were finally enrolled. The enrolment proportion ranged from 21-61% in 
the 72 WBC clusters and from 8-16% in the six TAUVRC-only clusters. 
 
All 45 974 subjects who received at least one dose of correct vaccine were included in ITT analyses. 
1392 children were excluded from effectiveness analysis: 1 381 children did not receive the treatment 
assigned to their cluster due to an error in the TAUVRC trial randomisation at the beginning of the 
study; 10 subjects did not receive any study vaccinations; and one subject was excluded due to lost 
source documentation (Figure 2). 
The mean follow-up was 25 months (range 15-35) for infants and 28 months (range 14-35) for 
subjects in the catch-up groups. The baseline and vaccination data presented in Table 1 shows 
similarity between the groups. 
 
Vaccine effectiveness against IPD 
From the administration of the first dose of study vaccine until the end of the blinded follow-up, a 
total of 26 culture-confirmed IPD cases were reported. Of these, three (serotypes 6B, 14 and 19A) 
occurred in the erroneously randomised TAUVRC infants and were therefore excluded from further 
analyses. All three received control vaccine instead of PHiD-CV10 vaccine.  
 
No vaccine-type IPD cases occurred after the first vaccine dose in the PHiD-CV10 3+1 infant group 
compared to 12 cases in the control group. Thus, VE was 100% (95% confidence interval 83-100%, 
table 2). One vaccine-type IPD due to serotype 7F was reported in a child receiving 2+1 infant 
schedule with PHiD-CV10, with VE of 92% (58-100%) compared to control group. This only case of 
vaccine-type IPD in any of the PHiD-CV10 cohorts occurred 12 days after the first vaccine dose 
given at 4 months of age. For the ATP follow-up period in the infant cohort, there were 11 cases of 
vaccine-type IPD in the control group compared to zero in the combined PHiD-CV10 groups meaning 
100% VE (91-100%).  
 
There were two cases of vaccine-related type IPD (6A and 19A) in the control infant group and one 
non-vaccine type IPD (serotype 3) in a fully vaccinated child in the PHiD-CV10 infant groups (table 
3). Any culture-confirmed IPD irrespective of serotype were reported for two subjects in combined 
PHiD-CV10 infant cohorts compared to 14 in the corresponding control cohorts (VE 93%, 75-99). 
With the incidence of 66 per 100 000 person-years in the control group for any culture-confirmed IPD, 
the absolute rate reduction was 61 per 100 000 person-years. 
 
Five cases of IPD due to serotype 6B were detected in the control infant cohorts compared to none in 
the PHiD-CV10 cohorts in the ITT follow-up (VE 100%, 77-100%). For serotype 14, the 
corresponding figures were 4 and 0, respectively (VE 100%, 71-100%). For other serotypes, only 
single cases were found (table 3).  
 
In addition to culture-confirmed cases, there were 3 probable, culture-negative IPD cases detected by 
AccuProbe (GEN-PROBE, San Diego, USA) directly from the blood-culture bottles, all in the control 
clusters (table 2). No sample was available for serotyping for these cases. 
 
For the catch-up cohorts, there were 7 cases of IPD, all in the control group. Of these, 2 and 5 were 
reported in children vaccinated with the first dose at 7-11 months of age and at 12-18 months of age, 
respectively (VE 100%, 79-100% for the latter cohort, Table 3, Appendix table 2).  
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All IPD cases were diagnosed at hospital emergency rooms and treated in hospital. There were neither 
fatal nor meningitis cases. Two of the cases in the control group were treated at intensive care unit. 
Further clinical details are available in Appendix table 2.  
In addition, there were eight cases of invasive diseases due to other bacteria, see Appendix table 3. 
 
Adverse events 
Twelve children died during the blinded follow-up of the FinIP trial. The deaths were equally 
distributed between the treatment groups (four in each of the PHiD-CV10 3+1, the PHiD-CV10 2+1 
and the combined control groups) and none were temporally associated with study vaccinations or 
considered related to trial participation. Causes of death in the control group were accidental 
asphyxiation (2), traffic accident (1), and Reye’s syndrome (1) and in the PHiD-CV10 groups genetic 
diseases (2), sudden death of unknown cause (2), and accidental asphyxiation, enteroviral disease, 
myocarditis, and sudden infant death syndrome (one of each). 
 
Additionally, non-fatal serious adverse events suspected to be vaccine-related by the reporting health 
care professional were reported for 18 children, nine of them the investigator categorised as possibly 
or definitely related to study vaccine. Among those, there were two febrile convulsions in the PHiD-
CV10 group and three in the control group, one hypotonic hyporesponsive episode in the control 
group, one local reaction with irritability and two cases of Kawasaki’s disease both in the PHiD-
CV10 group. Of the remaining nine cases, two IPD cases, one cystitis and one unspecified infection 
occurred in the control clusters, and two diarrhoea cases, one tonsillitis, one parotitis and one eczema 
with fever in the PHiD-CV10 clusters.   
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DISCUSSION 
 
The FinIP trial demonstrated excellent effectiveness of the PHiD-CV10 vaccine against invasive 
pneumococcal disease for all vaccination schedules assessed. The convincing effectiveness of the 
infant 2+1 schedule used in many national programmes was demonstrated for the first time in a 
clinical trial setting. Effectiveness was also shown against the two most common serotypes 6B and 
14. . We were not able to show serotype-specific effectiveness for any of the other serotypes 
(including serotypes 1, 5 and 7F) due to the low number or no cases. 
 
Our results are very similar to those of the NCKP trial
1
 assessing the PCV7 vaccine in 3+1 schedule 
in which the vaccine efficacy against vaccine-type IPD was 94% and against any IPD irrespective of 
serotype 89% in ITT follow-up. However, the results of the current trial and the NCKP trial compare 
favourably to the results of clinical trials conducted in populations with high IPD burden,
19–21
 in 
which lower point estimates of VE ranging from 42 to 53% for ITT follow-up against any IPD have 
been reported. In our trial similarly to the NCKP trial
1
, there was no indication of replacement disease, 
although the number of non-vaccine serotype IPDs was too low for inference.  
 
No safety concerns were observed during the FinIP trial. The number of deaths was comparable to the 
pre-trial baseline incidence, and balanced across treatment groups. The two cases of Kawasaki’s 
disease in the PHiD-CV10 group are much less than the expected number of 11 in all study subjects 
using the incidence of 11·4 per 100 000 person-years as a reference.
22,23
 
 
 
We consider our study data of high validity because of the randomised double-blind trial design with 
concurrent controls. The outcome data were collected from an established nationwide register. The 
laboratory-based surveillance has been mandatory for all hospital laboratories since 1995 and 
electronic reporting is used. From all reported culture-confirmed IPD cases, a bacterial isolate was 
available for serotyping. Furthermore, the trial follow-up was complete for all cases reported in the 
register as they were identified using the national Personal Identity Code, which is unique and 
permanent for all Finnish citizens given soon after birth or immigration.  
 
The baseline IPD incidence prior to study start during 2004 to 2008 was 63·1 per 100 000 person-
years in children under two years of age with the highest incidence in infants 10 to 21 months of age. 
Altogether 78% were caused by serotypes covered by the PHiD-CV10. The incidence is lower 
compared to US data before PCV7 but comparable to European incidence figures ranging from 54·2 
to 67·7 per 100 000 person-years in the corresponding age group.
3,4, 25
  
 
We failed to enrol high proportions of age-eligible children in all the clusters. The main reason was 
refusal to participate as the trial exclusion criteria mainly followed the contraindications of the NVP, 
coverage of which is extremely high (>95%). Based on hepatitis vaccination indications and PCV 
national sales statistics the commercial use of study vaccines was estimated low. The enrolment was 
substantially higher (44% vs. 24%) for birth cohorts of 2009 to 5/2010 compared to children born in 
2008 enrolled mainly in the catch-up cohorts. The enrolment was also lower in the clusters with 
exclusive TAUVRC enrolment, in the urban clusters in the biggest cities and in the Swedish-speaking 
areas. However, the IPD incidence in the control clusters during the trial was identical with the 
Finnish baseline observed before the study start, which suggests no major selection bias in study 
participation. 
 
 
Variability in the IPD incidence is associated with population characteristics, but also with diagnostic 
practices, especially use of blood cultures.
24,26
 The Finnish population is generally homogeneous, but 
access to treatment and diagnostic practices may vary between areas. However, variability in the IPD 
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incidence between the study clusters in 2004-2008 was low. Similar homogeneity was observed in the 
actual trial data. To minimise the risk of bias we chose to include high enough number of clusters to 
have more than one cluster in each major city and hospital district. Further assurance for 
comparability between treatment groups was sought through stratification of randomisation. 
 
PCV was introduced in 2+1 schedule into the Finnish National Vaccination Programme from 
September 1, 2010 for infants born on June 1, 2010 or later without catch-up vaccinations. Out of the 
total of 13, five cases of vaccine-type IPD occurred before the start of the NVP and six cases within 
one year of the NVP start and only two cases thereafter. Should the NVP have had any effect on the 
study results, it would have diluted the VE estimates by reducing IPD incidence primarily in the 
control clusters with no direct protection.  
 
Vaccine effectiveness demonstrated in our nationwide population-based field trial with considerable 
enrolment proportion is best fitted to predict the impact of corresponding vaccination programmes in 
developed country settings. Accordingly, the early national surveillance data available following the 
introduction of PHiD-CV10 in the NVP shows a marked reduction in infant IPD in Finland
27 
and in 
Quebec, Canada.
28
 
 
Vaccination with PCV7 has already shown a considerable impact on public health burden of 
pneumococcal diseases among the vaccine recipients in different countries. The effectiveness of 
PHiD-CV10 against IPD shown in the current study confirms that at least similar reduction in disease 
burden can be expected with this vaccine. Moreover, additional benefit for vaccinees can be 
anticipated through vaccine impact on pneumonia
29
 and otitis media.
12
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TABLES 
 
Table 1: Characteristics of study participants and vaccination data for the different treatment arms 
 PHiD-CV10 group Control group 
Infants (<7 months of age) 3+1 schedule 2+1 schedule 3+1 schedule 2+1 schedule 
Number of participants N=10273 N=10054 N=4941 N=5259 
Male gender, % 49•8 51•4 51•6 50•7 
Gestational age, <37 weeks, % 4•6 5•5 5•2 4•6 
Birth weight, <2500 g, % 3•2 3•8 4•2 3•1 
Age at first dose of study vaccine, weeks, median (range) 14 (6 to 31) 14 (5 to 30) 14 (6 to 30) 14 (6 to 30) 
Subjects with complete primary vaccination series schedule, % 96•7 98•5 97•3 99•3 
Follow-up time in months, mean 25•1 24•6  24•7 25•3 
     
Children (7-11 months of age)   
Number of participants N=3880 N=1907 
Male gender, %  51•3 51•6 
Gestational age, <37 weeks, %  5•9 6•6 
Birth weight, <2500 g, %  4•3 5•2 
Age at first dose of study vaccine, weeks, median (range) 40 (30 to 52) 40 (30 to 52) 
Subjects with complete primary vaccination series schedule (2 
doses), %  
97•8 98•6 
Follow-up time in months, mean 27•8 28•1 
   
Children (12-18 months of age)   
Number of participants N=6534 N=3126 
Male gender, % 51•1 51•1 
Gestational age, <37 weeks, %  5•9 6•2 
Birth weight, <2500 g, %  4•5 4•1 
Age at first dose of study vaccine, weeks, median (range) 63 (52 to 93) 64 (52 to 91) 
Subjects with complete 2-dose vaccination series, %  92•9 93•6 
Follow-up time in months, mean 28•2 28•5 
 
 
      18 
Table 2: Episodes of invasive pneumococcal disease (IPD) and the vaccine effectiveness for the 10-valent PHiD-CV in vaccinated infants enrolled 
at the age of <7 months, intention-to-treat analysis unless stated otherwise. 
 Number 
of episodes 
Number of clusters 
with at least one 
episode 
Follow-up time, 
person-years 
Incidence, per 
100 000 person-
years 
Vaccine 
effectiveness 
Endpoint definition and vaccinated 
cohort 
PHiD-CV10 
group 
Control 
group 
PHiD-CV10 
group 
Control 
group 
PHiD-CV10 
group 
Control 
group 
PHiD-CV10 
group 
Control 
group 
VE point 
estimate 
95% CI 
Culture-confirmed vaccine-type 
IPD, 3+1 schedule from dose 1 
0 12 0 10 21502 21292 0 56•4 100 83-100 
Culture-confirmed vaccine-type 
IPD, 2+1 schedule from dose 1 
1 12 1 10 20647 21292 4•8 56•4 92 58-100 
Culture-confirmed vaccine-type 
IPD, 3+1 and 2+1 schedule 
combined, per protocol follow-
up 
0 11 0 9 36882 18660 0 58•9 100 91-100 
Culture-confirmed IPD irrespective 
of serotype, 3+1 and 2+1 
schedule combined from dose 1 
2 14 2 11 42149 21292 4•7 65•8 93 75-99 
Culture-confirmed or probable IPD, 
3+1 and 2+1 schedule combined 
from dose 1 
2 17 2 11 42149 21292 4•7 79•8 94 77-99 
culture-confirmed IPD, S. pneumoniae isolated from normally sterile body fluids by culture; probable IPD, demonstration of S. pneumoniae from 
normally sterile body fluids based on nucleic acid and/or antigen detection tests only, without isolation by culture
      19 
Table 3: Number of episodes of culture-confirmed invasive pneumococcal disease (IPD) by serotype.  
Serotype Control group, 
children enrolled 
at <7 months of 
age 
PHiD-CV10 group, 
children enrolled at 
<7 months of age, 
combined* 
Control group, 
children enrolled 
at 7-11 months of 
age 
PHiD-CV10 group,  
children enrolled at 
7-11 months of age 
Control group, 
children enrolled 
at 12-18 months 
of age 
PHiD-CV10 group,  
children enrolled at 
12-18 months of 
age 
Follow-up years 21292 42149 4479 9001 7421 15358 
Vaccine serotypes       
1       
4     1  
5       
6B 5    1  
7F  1 1    
9V       
14 4    1  
18C 1      
19F 1  1    
23F 1      
Subtotal 12 1 2 0 3 0 
       
Vaccine-related 
serotypes ** 
      
6A 1      
19A 1      
Subtotal 2 0 0 0 0 0 
       
Other serotypes       
3  1   1  
15C     1  
Subtotal 0 1 0 0 2 0 
       
TOTAL 14 2 2 0 5 0 
 
* both IPD cases in 2+1 group 
** belonging into the same serogroup as vaccine serotypes 
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Appendix table 1: Vaccines included in the Finnish National Vaccination Programme offered for children under 36 months of age during the trial 
conduct which were commonly given concomitantly with the study vaccinations. 
Vaccination Vaccine Doses Schedule Comments 
BCG BCG Vaccine SSI™  
(Statens Serum Institut) 
1 at birth Risk groups only 
Rota RotaTeq™  
(Sanofi Pasteur MSD) 
3 2, 3, 5 months Started in September 2009  
DTaP/IPV/Hib Infanrix-IPV+Hib™  
(GSK Vaccines)  
3 3, 5, 12 months  
MMR M-M-RVaxPro™  
(Sanofi Pasteur MSD) 
1 15 to 18 months  
Influenza several in use 1 or 2 yearly Starting in November each year;  
first vaccination 2 doses, then 1 only 
Pandemic Influenza AH1N1 Pandemrix™  
(GSK Vaccines) 
1 from 6 months onwards Between November 2009 to March 2010 
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Appendix table 2: Cases of culture-confirmed and probable invasive pneumococcal disease.  
List 
case 
Study vaccine 
administered 
Serotype Age at 
enrolment
, months 
Age at invasive 
disease, 
months 
Month and 
year of the case 
Relevant medical 
history 
Clinical syndrome 
1 PHiD-CV10 2+1 7F 4 4 DEC2009 None Septic arthritis 
2 PHiD-CV10 2+1 3 2 17 FEB2011 None, previous Infant 
Respiratory Distress 
Syndrome 
Bacteremic pneumonia 
3 Control 3+1 6A 6 8 JUL2010 None Bacteremia 
4 Control 2+1 6B 3 12 FEB2011 Eczema atopic Bacteremia 
5 Control 2+1 6B 5 16 MAY2010 None Bacteremia 
6 Control 2+1 6B 4 17 FEB2011 None Bacteremia 
7 Control 2+1 6B 3 10 FEB2011 None Bacteremic pneumonia 
8 Control 3+1 6B 5 19 MAR2011 None Bacteremia 
9 Control 3+1 14 5 10 NOV2009 Eczema atopic Bacteremia 
10 Control 3+1 14 3 13 JUL2010 Food allergy Bacteremia 
11 Control 3+1 14 6 23 DEC2010 None Bacteremia 
12 Control 3+1 14 1 20 APR2011 Asthma, post-infectious Bacteremic pneumonia 
13 Control 3+1 18C 5 16 JUN2010 Low birth weight,  
Small for gestational age 
Bacteremia 
14 Control 3+1 19A 2 18 OCT2011 None Bacteremic pneumonia/ 
empyema 
15 Control 2+1 19F 3 21 JAN2012 None Bacteremia 
16 Control 3+1 23F 3 25 JAN2012 None Bacteremia 
17 Control 3+1 NA,  
probable 
IPD 
4 15 DEC2010 None Bacteremia 
18 Control 3+1 NA,  
probable 
IPD 
1 12 MAY2011 Eczema atopic Bacteremic pneumonia 
      22 
19 Control 3+1 NA,  
probable 
IPD 
2 19 OCT2011 None Bacteremic pneumonia 
20 Control 3+1* 6B 2 20 OCT2010 None Bacteremia 
21 Control 3+1* 14 1 11 FEB2010 Food allergy Bacteremic pneumonia 
22 Control 3+1* 19A 2 10 NOV2009 None Bacteremia 
23 Control catch-up 7F 10 10 AUG2009 None Bacteremia 
24 Control catch-up 14 9 17 APR2010 None Bacteremia 
25 Control catch-up 3 14 44 SEP2011 None Bacteremic pneumonia 
26 Control catch-up 4 12 20 JUN2010 Food allergy Bacteremia 
27 Control catch-up 6B 18 30 OCT2010 None Bacteremia 
28 Control catch-up 15C 14 40 OCT2011 None, previously 
hydronephrosis 
Bacteremia 
29 Control catch-up 19F 18 30 OCT2010 None Bacteremia 
* subject eliminated from the ITT effectiveness analyses due to randomisation error  
All cases were detected from blood culture samples; culture-confirmed IPD, S. pneumoniae isolated by culture; probable IPD, demonstration of S. 
pneumoniae based on nucleic acid and/or antigen detection tests only, without isolation by culture 
NA- not available 
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Appendix table 3: Cases of culture-confirmed invasive diseases due to other bacteria. 
List 
case 
Study vaccine 
administered 
Pathogen Age at 
enrolment, 
months 
Age at 
invasive 
disease, 
months 
Month and 
year of the ID 
case 
Relevant medical 
history 
Sample 
positive 
Clinical syndrome 
1 Control 2+1 S. pyogenes 5 17 MAR2010 
None, varicella 
in a week 
preceding ID 
Blood 
Bacteremic pneumonia/ 
Septic arthritis 
2 Control 2+1 S. pyogenes 2 24 MAR2011 None Blood Bacteremia 
3 Control 2+1 N. meningitidis 3 3 NOV2009 None Blood Meningitis 
4 PHiD-CV10 2+1 N. meningitidis 6 15 NOV2010 None 
Cerebrospinal 
fluid and blood 
Meningitis 
5 PHiD-CV10 3+1 N. meningitidis 1 5 SEP2009 None Blood Bacteremia 
6 PHiD-CV10 3+1 N. meningitidis 3 13 MAY2011 None 
Cerebrospinal 
fluid 
Meningitis 
7 PHiD-CV10 2+1 H. influenzae, non-typable 2 20 DEC2011 Food allergy Blood 
Bacteremic 
pneumonia/empyema 
8 Control 3+1 
H. influenzae, non-
typable + M. catarrhalis 
2 23 SEP2011 None Blood Bacteremia 
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FIGURE LEGENDS 
 
Figure 1. Map of Finland with trial municipalities and treatment groups. Treatment groups are indicated with different colors and the lines represent 
the boundaries of Finnish municipalities, the number of which ranged from 1 to 12 per cluster. Six biggest cities included several clusters. 
 
Figure 2. Trial profile for the subjects  
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Finnish- or Swedish-speaking parents of age-eligible children found in Population register  
contacted by mailed invitation letters, N=125000 
 Did not participate  n~77000 
Number of children enrolled N=47366 
Study 043 (NCT00861380) N= 41188 
Study 053 (NCT00839254) N= 6178*  
 
15878 subjects 
 infants <7 months, N=10275 
 catch-up 7-11 months, N=2169 
 catch-up 12-18 months, N=3434  
 
15368 subjects 
 infants <7 months, N=10426 
 catch-up 7-11 months, N=1761 
 catch-up 12-18 months, N= 3181 
 
8442 subjects 
 infants <7 months, N=5550 
 catch-up 7-11 months, N=1161 
 catch-up 12-18 months, N= 1731 
 
7675 subjects 
 infants <7 months, N=5259 
 catch-up 7-11 months, N=855 
 catch-up 12-18 months, N= 1561 
 
15876 subjects 
 infants <7 months, N=10273; excluded 
o 2 with no vaccinations 
 catch-up 7-11 months, N=2169 
o no exclusions 
 catch-up 12-18 months, N=3434 
o no exclusions 
14865 subjects 
 infants <7 months, N=10054**; excluded 
o 371 due to randomisation error 
o 1 with no vaccinations 
 catch-up 7-11 months, N= 1711; excluded 
o 50 due to randomisation error 
 catch-up 12-18 months, N= 3100; excluded 
o 81 due to randomisation error 
 
7559 subjects 
 infants <7 months, N=4941; excluded 
o 605 due to randomisation error 
o 4 with no vaccinations 
 catch-up 7-11 months, N=1053; excluded 
o 108 due to randomisation error 
 catch-up 12-18 months, N=1565; excluded 
o 166 due to randomisation error 
 
7674 subjects 
 infants <7 months, N=5259** 
o no exclusions 
 catch-up 7-11 months, N= 854; excluded 
o 1 with source documents lost 
 catch-up 12-18 months, N= 1561 
o no exclusions 
 
 infants <7 months, N=9960; excluded 
o 70 due to pneumococcal vaccinations  
o 12 with at least one study vaccine dose 
not as planned 
o 2 due to wrong age at study enrolment 
o 7 vaccine temperature deviations 
o 1 randomisation failure 
o 2 participating in another trial 
 
 infants <7 months, N=4868; excluded 
o 58 pneumococcal vaccinations 
o 6 with at least one study vaccine dose 
not as planned 
o 1 due to wrong age at study enrolment 
o 4 vaccine temperature deviation 
o 1 code broken 
o 3 randomisation failures 
 infants <7 months, N=5185; excluded 
o 65 pneumococcal vaccinations 
o 1 with at least one study vaccine dose 
not as planned 
o 3 due to wrong age at study 
enrolment  
o 2 vaccine temperature deviation 
o 3 randomisation failures 
78 randomised clusters (ratio 2:2:1:1)  
 PHiD-CV10 3+1 PHiD-CV10 2+1 Control 3+1 Control 2+1 
 26 clusters 26 clusters 13 clusters 13 clusters 
 
 infants <7 months, N=10227; excluded 
o 33 pneumococcal vaccinations 
o 8 with at least one study vaccine dose 
not as planned 
o 3 due to wrong age at study 
enrolment 
o 1 vaccine temperature deviation 
o 1 code broken 
 
Invited 
 
 
 
 
 
Total enrolled  
 
 
 
Random 
Allocation 
 
 
Enrolled by group 
 
 
 
 
Intention to treat 
follow-up  
 
 
 
 
 
 
According to 
protocol (ATP) 
follow-up  
 
for 
infants <7 months 
 
  * 3 subjects not randomised nor vaccinated 
 ** includes one subject withdrawn from the register follow-up during the blinded follow-up period 
